Evidence map›Paper›PMID 32382011›Full record

ArticleNature communications2020

Author Correction: Repurposing endogenous immune pathways to tailor and control chimeric antigen receptor T cell functionality.

Mohit Sachdeva, Brian W Busser, Sonal Temburni, Billal Jahangiri, Anne-Sophie Gautron, Alan Maréchal, Alexandre Juillerat, Alan Williams, Stéphane Depil, Philippe Duchateau and 2 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Mohit SachdevaCellectis, Inc., 430 East 29th Street, New York, NY, 10016, USA.
Brian W BusserCellectis, Inc., 430 East 29th Street, New York, NY, 10016, USA.
Sonal TemburniCellectis, Inc., 430 East 29th Street, New York, NY, 10016, USA.ORCID http://orcid.org/0000-0001-6690-7746
Billal JahangiriCellectis, Inc., 430 East 29th Street, New York, NY, 10016, USA.ORCID http://orcid.org/0000-0001-6512-0693
Anne-Sophie GautronCellectis, 8 rue de la Croix Jarry, 75013, Paris, France.
Alan MaréchalCellectis, 8 rue de la Croix Jarry, 75013, Paris, France.
Alexandre JuilleratCellectis, Inc., 430 East 29th Street, New York, NY, 10016, USA.ORCID http://orcid.org/0000-0001-9800-6168
Alan WilliamsCellectis, Inc., 430 East 29th Street, New York, NY, 10016, USA.
Stéphane DepilCellectis, 8 rue de la Croix Jarry, 75013, Paris, France.
Philippe DuchateauCellectis, 8 rue de la Croix Jarry, 75013, Paris, France.ORCID http://orcid.org/0000-0002-3491-9168
Laurent PoirotCellectis, 8 rue de la Croix Jarry, 75013, Paris, France.ORCID http://orcid.org/0000-0002-5028-2267
Julien ValtonCellectis, Inc., 430 East 29th Street, New York, NY, 10016, USA. julien.valton@cellectis.com.ORCID http://orcid.org/0000-0003-0826-5401

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32382011
PMCPMC7205966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.